BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Thai Nippon Rubber Industry PCL
SET:TNR
|
TH |
|
V
|
Vicostone JSC
VN:VCS
|
VN |
|
Blackfinch Spring VCT PLC
LSE:BFSP
|
UK |
|
China Construction Bank Corp
OTC:CICHF
|
CN |
|
X
|
Xplora Technologies AS
OSE:XPLRA
|
NO |
|
Tanvi Foods (India) Ltd
BSE:540332
|
IN |
|
T
|
TransThera Sciences (Nanjing) Inc
HKEX:2617
|
CN |
|
I
|
InterCard Informationssysteme AG
F:II8
|
DE |
|
Ariana Resources PLC
LSE:AAU
|
UK |
|
Sharda Cropchem Ltd
NSE:SHARDACROP
|
IN |
|
S
|
Shannon Semiconductor Technology Co Ltd
SZSE:300475
|
CN |
|
International Isotopes Inc
OTC:INIS
|
US |
BiVictriX Therapeutics PLC
Research & Development
BiVictriX Therapeutics PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Research & Development
-£1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$240.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Research & Development
-£274.9m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$118.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
-£5.1m
|
CAGR 3-Years
56%
|
CAGR 5-Years
30%
|
CAGR 10-Years
13%
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
See Also
What is BiVictriX Therapeutics PLC's Research & Development?
Research & Development
-1.9m
GBP
Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Research & Development amounts to -1.9m GBP.
What is BiVictriX Therapeutics PLC's Research & Development growth rate?
Research & Development CAGR 1Y
4%
Over the last year, the Research & Development growth was 4%.
